Laurus Labs Ltd. (LAURUSLABS) AI Stock Analysis

• Market Cap: ₹465.90B
• Dividend Yield: 0.14%
• Average Volume (3M): 62.23K
• Price to Earnings (P/E): 91.5
• Beta (1Y): 1.28
• Revenue Growth: 17.31%
• EPS Growth: 242.99%
• Country: IN
• Employees: 6,007
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 3.00
• Shares Outstanding: 539,824,900
• 10 Day Avg. Volume: 56,464
• 30 Day Avg. Volume: 62,227
• PEG Ratio: 0.73
• Price to Book (P/B): 7.23
• Price to Sales (P/S): 5.82
• P/FCF Ratio: -821.32
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹660.80
• Price Target Upside: -23.82% Downside
• Rating Consensus: Strong Sell
• Number of Analyst Covering: 5

• Rating: 55 Neutral
• Price Target: ₹894.00 ▲(3.06% Upside)

Laurus Labs' overall stock score is primarily influenced by its financial performance, which shows strong revenue growth but faces profitability and cash flow challenges. Technical analysis indicates a lack of strong momentum, with potential for a rebound. Valuation concerns due to a high P/E ratio and minimal dividend yield further impact the score.

Laurus Labs Ltd. Business Overview & Revenue Model

Company Description

Laurus Labs Ltd. is an Indian-based pharmaceutical company engaged in the development, manufacture, and sale of active pharmaceutical ingredients (APIs), generic formulations, and contract research services. The company operates in several key sectors, including anti-retrovirals, oncology, cardiovascular, anti-diabetics, and other therapeutic segments. Laurus Labs leverages its extensive R&D capabilities to innovate and deliver high-quality pharmaceutical products globally.

How the Company Makes Money

Laurus Labs Ltd. makes money primarily through the sale of its active pharmaceutical ingredients (APIs) and generic formulations. The company's revenue model is largely driven by its robust pipeline of APIs, which are supplied to various pharmaceutical companies for the production of finished dosage forms. Additionally, Laurus Labs generates income from its generic formulations business, where it manufactures and sells ready-to-use pharmaceutical products. The company also offers contract research and manufacturing services (CRAMS), providing custom synthesis and process development for other pharmaceutical firms. Strategic partnerships and collaborations with other global players in the pharmaceutical industry further augment its revenue streams.

Laurus Labs Ltd. Financial Statement Overview

Summary

Laurus Labs exhibits strong revenue growth and efficient cost management, but profitability margins are under pressure. The balance sheet shows moderate leverage with increasing liabilities, and cash flow challenges due to high capital expenditures need addressing to ensure liquidity stability.

Income Statement

Laurus Labs has shown consistent revenue growth, with a notable increase from 2024 to 2025. The gross profit margin remains strong, indicating effective cost management. However, the net profit margin has decreased due to rising expenses, impacting overall profitability.

Balance Sheet

The company maintains a balanced debt-to-equity ratio, reflecting moderate leverage. However, the equity ratio shows a declining trend, indicating increased liabilities relative to assets. Return on equity has weakened, reflecting a dip in profitability.

Cash Flow

Operating cash flow has remained relatively stable, but free cash flow is negative due to high capital expenditures. The free cash flow to net income ratio indicates potential cash flow challenges impacting liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	59.29B	55.54B	50.41B	60.41B	48.89B	47.23B
Gross Profit	33.50B	30.76B	25.03B	31.74B	26.40B	25.26B
EBITDA	12.88B	10.55B	8.01B	15.76B	14.11B	15.61B
Net Income	5.09B	3.58B	1.61B	7.90B	8.28B	9.84B
Balance Sheet
Total Assets	0.00	93.36B	83.87B	76.60B	69.68B	57.51B
Cash, Cash Equivalents and Short-Term Investments	1.44B	1.44B	1.42B	484.60M	759.40M	484.60M
Total Debt	0.00	27.64B	25.77B	20.15B	17.77B	14.82B
Total Liabilities	-46.03B	47.33B	42.71B	36.12B	36.09B	31.50B
Stockholders Equity	46.03B	44.73B	41.11B	40.38B	33.51B	25.98B
Cash Flow
Free Cash Flow	0.00	-393.50M	-126.20M	37.40M	342.60M	442.30M
Operating Cash Flow	0.00	6.02B	6.66B	9.94B	9.11B	7.33B
Investing Cash Flow	0.00	-6.82B	-8.22B	-9.96B	-9.14B	-9.41B
Financing Cash Flow	0.00	392.80M	2.50B	-266.40M	302.60M	2.55B

Laurus Labs Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 867.45
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LAURUSLABS, the sentiment is Positive. The current price of 867.45 is below the 20-day moving average (MA) of 882.69, below the 50-day MA of 873.27, and above the 200-day MA of 689.94, indicating a neutral trend. The MACD of -3.82 indicates Positive momentum. The RSI at 48.07 is Neutral, neither overbought nor oversold. The STOCH value of 48.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LAURUSLABS.

Laurus Labs Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GLAND	69 Neutral	₹319.56B	41.49	―	0.93%	-2.34%	6.64%
SUVENPHAR	64 Neutral	₹329.37B	93.64	―	―	62.25%	-0.32%
BIOCON	60 Neutral	₹465.31B	108.79	―	0.14%	6.80%	-75.66%
IPCALAB	60 Neutral	₹344.91B	44.30	―	0.30%	11.49%	35.00%
LAURUSLABS	55 Neutral	₹465.90B	91.49	―	0.14%	17.31%	242.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLENMARK	48 Neutral	₹543.41B	72.10	―	0.13%	10.99%	―

Laurus Labs Ltd. Corporate Events

Laurus Labs Secures Land for Major Expansion in Andhra Pradesh

Laurus Labs Ltd. has been allotted 531.77 acres of land by the Government of Andhra Pradesh in Anakapalli District for the establishment of Laurus Pharma Zone (LPZ). This strategic move involves an investment of 5,630 Crores and aims to create 6,350 jobs over eight years, marking a significant step in the company’s expansion plans and strengthening its position in the pharmaceutical industry.

Laurus Labs Conducts 20th AGM with Key Stakeholders

Laurus Labs Ltd. held its 20th Annual General Meeting (AGM) on June 26, 2025, via video conferencing. The meeting was attended by key directors and stakeholders, including the Executive Director and CEO, Dr. Chava Satyanarayana, and other board members. A total of 109 participants, representing over 152 million shares, joined the meeting. The AGM proceedings are part of the company’s compliance with SEBI regulations, ensuring transparency and engagement with shareholders.

Laurus Labs Conducts 20th AGM with E-Voting Transparency

Laurus Labs Ltd. held its 20th Annual General Meeting (AGM) on June 26, 2025, conducted through video conferencing with e-voting facilitated by NSDL. The scrutinizer’s report, prepared by Y. Ravi Prasada Reddy, confirmed the participation of 1,433 members in the voting process, highlighting the company’s commitment to transparency and shareholder engagement.